Often used for:
Hodgkin lymphoma, B-cell lymphoma, melanoma, hepatocellular carcinoma, other cancers
What is pembrolizumab?
Pembrolizumab is a programmed cell death-1 (PD-1) blocking antibody that enhances the immune system's ability to attack cancer cells. It is administered by IV infusion, often every 3 weeks, with close monitoring of vital signs and lab work.
Possible side effects
- Fatigue or weakness
- Bone, joint, or muscle pain
- Loss of appetite or weight loss
- Abdominal pain
- Diarrhea or constipation
- Rash, itching, or dry skin
- Cough or shortness of breath
- Thyroid problems
- High blood sugar or low sodium
- Low blood counts
- Flu-like symptoms (fever, chills)
- Nausea or vomiting
- Swelling or headache
- Dizziness or sleep problems
- Cold-like symptoms
- Peripheral neuropathy
- Liver or kidney problems
- Infusion-related reactions
- Serious complications after allogeneic stem cell transplant
- Not all patients experience these side effects. Report all symptoms.
Tips for families
- Inform the nurse immediately if symptoms occur during infusion.
- Premedications like diphenhydramine and acetaminophen may be recommended.
- Follow care team guidance to manage nausea, diarrhea, or constipation.
- Use birth control during treatment and for 4 months after therapy.
- Tell the doctor if pregnant or breastfeeding.
